Clarifying the molecular pathophysiology and phenotypic spectrum of GJB2-related hearing loss is essential to define the natural history of GJB2 deafness and lay the clinical foundation for future gene, cell, and drug-based therapeutics. The gene discussed is GJB2; the disease is deafness.